结直肠肛门外科2025，Vol.31Issue(4)：365-370,6.DOI:10.19668/j.cnki.issn1674-0491.2025.04.017
RSL3诱导铁死亡治疗结直肠癌的研究进展
Research progress of RSL3-induced ferroptosis in the treatment of colorectal cancer
卫奕凡 1叶超 2张少华 1蒋英杰2
作者信息
- 1. 海军军医大学第一附属医院肛肠外科 上海 200433
- 2. 海军军医大学第一附属医院病理科 上海 200433
- 折叠
摘要
Abstract
Colorectal cancer(CRC)ranks as the second leading cause of cancer-related mortality worldwide,with an in-creasing incidence among younger populations.Beyond surgical intervention,clinical management of CRC primarily in-volves chemotherapy,immunotherapy,and targeted therapy.In recent years,ferroptosis-a form of regulated cell death driven by iron-dependent lipid peroxidation-has emerged as a promising therapeutic target,with its critical role in CRC development and treatment gradually being uncovered.RSL3,an inhibitor of glutathione peroxidase 4,effectively triggers ferroptosis and demonstrates significant antitumor effects.This article reviews recent advances in RSL3-induced ferropto-sis for CRC treatment,analyzing its molecular mechanisms,synergistic effects with other therapies,and relationship with the tumor microenvironment,while discussing challenges and future research directions.关键词
结直肠癌/铁死亡/RSL3/谷胱甘肽过氧化物酶4Key words
colorectal cancer/ferroptosis/RSL3/glutathione peroxidase 4分类
医药卫生引用本文复制引用
卫奕凡,叶超,张少华,蒋英杰..RSL3诱导铁死亡治疗结直肠癌的研究进展[J].结直肠肛门外科,2025,31(4):365-370,6.
